Cell-Free Placental DNA in Maternal Plasma in Relation to Placental Health and Function

Fetal Diagnosis and Therapy

Volumn 41, Issue 4, 2017, Pages 258-264

  Manokhina, Irina ^a   Singh, Tanjot K ^a   Robinson, Wendy P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell free DNA; Intrauterine growth restriction; Preeclampsia; Pregnancy; Prenatal screening; Preterm birth

Indexed keywords

CELL FREE PLACENTAL DNA; CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA; PLASMA PROTEIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL FREE NUCLEIC ACID;

ANEUPLOIDY; ARTICLE; CHROMOSOME ABERRATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; FETUS GROWTH; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MATERNAL PLASMA; MOSAICISM; PLACENTA DISORDER; PLACENTA WEIGHT; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; PROMOTER REGION; TROPHOBLAST; BLOOD; MATERNAL SERUM SCREENING TEST; METABOLISM; PHYSIOLOGY; PLACENTA; PLASMA; PREGNANCY; PROCEDURES;

BIOMARKERS; CELL-FREE NUCLEIC ACIDS; COHORT STUDIES; FEMALE; HUMANS; MATERNAL SERUM SCREENING TESTS; PLACENTA; PLASMA; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84991696103     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000448707     Document Type: Article

References (38)

1. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS: Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-487.
2. Ferres MA, Hui L, Bianchi DW: Antenatal noninvasive DNA testing: clinical experience and impact. Am J Perinatol 2014; 31: 577-582.
3. Bischoff FZ, Lewis DE, Simpson JL: Cell-free fetal DNA in maternal blood: kinetics, source and structure. Hum Reprod Update 2005; 11: 59-67.
4. Alberry M, Maddocks D, Jones M, Abdel Hadi M, Abdel-Fattah S, Avent N, Soothill P: Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenat Diagn 2007; 27: 415-418.
5. Flori E, Doray B, Gautier E, Kohler M, Ernault P, Flori J, Costa JM: Circulating cell-free fetal DNA in maternal serum appears to originate from cyto-and syncytio-trophoblastic cells. Case report. Hum Reprod 2004; 19: 723-724.
6. Grati FR, Malvestiti F, Ferreira JC, Bajaj K, Gaetani E, Agrati C, Grimi B, Dulcetti F, Ruggeri AM, De Toffol S: Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med 2014; 16: 620-624.
7. Manokhina I, Wilson SL, Robinson WP: Noninvasive nucleic acid-based approaches to monitor placental health and predict pregnancy-related complications. Obstet Gynecol 2015; 213:S197-S206.
8. Sifakis S, Koukou Z, Spandidos DA: Cell-free fetal DNA and pregnancy-related complications (Review). Mol Med Rep 2015; 11: 2367-2372.
9. Lazar L, Nagy B, Ban Z, Nagy GR, Papp Z: Presence of cell-free fetal DNA in plasma of women with ectopic pregnancies. Clin Chem 2006; 52: 1599-1601.
10. Sekizawa A, Jimbo M, Saito H, Iwasaki M, Sugito Y, Yukimoto Y, Otsuka J, Okai T: Increased cell-free fetal DNA in plasma of two women with invasive placenta. Clin Chem 2002; 48: 353-354.
11. Nicolaides KH, Syngelaki A, del Mar Gil M, Quezada MS, Zinevich Y: Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal Diagn Ther 2014; 35: 212-217.
12. Ashoor G, Syngelaki A, Poon L, Rezende J, Nicolaides K: Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 2013; 41: 26-32.
13. Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, Lau TK, Chim SS, Chung GT, Nicolaides KH, Lo YM: Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006; 52: 2211-2218.
14. Chiu RW, Chim SS, Wong IH, Wong CS, Lee W, To KF, Tong JH, Yuen RK, Shum AS, Chan JK: Hypermethylation of RASSF1A in human and rhesus placentas. Am J Pathol 2007; 170: 941-950.
15. Sekizawa A, Sugito Y, Iwasaki M, Watanabe A, Jimbo M, Hoshi S, Saito H, Okai T: Cellfree fetal DNA is increased in plasma of women with hyperemesis gravidarum. Clin Chem 2001; 47: 2164-2165.
16. Poon L, Musci T, Song K, Syngelaki A, Nicolaides K: Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther 2013; 33: 215-223.
17. Blair JD, Yuen RK, Lim BK, McFadden DE, von Dadelszen P, Robinson WP: Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia. Mol Hum Reprod 2013; 19: 697-708.
18. Robinson WP, Penaherrera MS, Jiang R, Avila L, Sloan J, McFadden DE, Langlois S, von Dadelszen P: Assessing the role of placental trisomy in preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30: 1-8.
19. Lausman A, McCarthy FP, Walker M: Screening, diagnosis, and management of intrauterine growth restriction. J Obstet Gynaecol Can 2012; 34: 17-28.
20. Von Dadelszen P, Magee LA, Roberts JM: Subclassification of preeclampsia. Hypertens Pregnancy 2003; 22: 143-148.
21. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Breart G; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System: A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001; 108:E35.
22. Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84.
23. Muller SP, Bartels I, Stein W, Emons G, Gutensohn K, Legler TJ: Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn 2011; 31: 1300-1304.
24. Manokhina I, Singh TK, Penaherrera MS, Robinson WP: Quantification of cell-free DNA in normal and complicated pregnancies: overcoming biological and technical issues. PLoS One 2014; 9:e101500.
25. Royston P, Wright E: How to construct 'normal ranges' for fetal variables. Ultrasound Obstet Gynecol 1998; 11: 30-38.
26. Alberry MS, Maddocks DG, Hadi MA, Metawi H, Hunt LP, Abdel-Fattah SA, Avent ND, Soothill PW: Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009; 200: 98.e1-6.
27. Attilakos G, Maddocks DG, Davies T, Hunt LP, Avent ND, Soothill PW, Grant SR: Quantification of free fetal DNA in multiple pregnancies and relationship with chorionicity. Prenat Diagn 2011; 31: 967-972.
28. Lapaire O, Volgmann T, Grill S, Hosli I, Zanetti-Daellenbach R, Zhong XY, Holzgreve W: Significant correlation between maternal body mass index at delivery and in the second trimester, and second trimester circulating total cell-free DNA levels. Reprod Sci 2009; 16: 274-279.
29. Vora NL, Johnson KL, Basu S, Catalano PM, Hauguel-De Mouzon S, Bianchi DW: A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat Diagn 2012; 32: 912-914.
30. Wataganara T, LeShane ES, Farina A, Messerlian GM, Lee T, Canick JA, Bianchi DW: Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum Genet 2003; 112: 204-208.
31. Wataganara T, Metzenbauer M, Peter I, Johnson KL, Bianchi DW: Placental volume, as measured by 3-dimensional sonography and levels of maternal plasma cell-free fetal DNA. Obstet Gynecol 2005; 193: 496-500.
32. Frendo J, Guibourdenche J, Pidoux G, Vidaud M, Luton D, Giovangrandi Y, Porquet D, Muller F, Evain-Brion D: Trophoblast production of a weakly bioactive human chorionic gonadotropin in trisomy 21-affected pregnancy. J Clin Endocrinol Metab 2004; 89: 727-732.
33. Gagnon A, Wilson R, Audibert F, Allen V, Blight C, Brock J, Desilets V, Johnson J, Langlois S, Summers A: Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008; 30: 918-949.
34. Salvianti F, Inversetti A, Smid M, Valsecchi L, Candiani M, Pazzagli M, Cremonesi L, Ferrari M, Pinzani P, Galbiati S: Prospective evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia. Placenta 2015; 36: 996-1001.
35. Crowley A, Martin C, Fitzpatrick P, Sheils O, O'Herlihy C, O'Leary J, Byrne B: Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn 2007; 27: 174-179.
36. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF, Wataganara T, Romero R, Bianchi DW: Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 2004; 190: 707-713.
37. Al Nakib M, Desbriere R, Bonello N, Bretelle F, Boubli L, Gabert J, Levy-Mozziconacci A: Total and fetal cell-free DNA analysis in maternal blood as markers of placental insufficiency in intrauterine growth restriction. Fetal Diagn Ther 2009; 26: 24-28.
38. Eberle AM, Levesque D, Vintzileos AM, Egan JF, Tsapanos V, Salafia CM: Placental pathology in discordant twins. Obstet Gynecol 1993; 169: 931-935.